TG Therapeutics, Inc. (NASDAQ:TGTX) – Investment analysts at Jefferies Group upped their FY2017 earnings per share (EPS) estimates for shares of TG Therapeutics in a report issued on Thursday. Jefferies Group analyst M. Andrews now expects that the biopharmaceutical company will post earnings of ($1.77) per share for the year, up from their prior estimate of ($1.84). Jefferies Group also issued estimates for TG Therapeutics’ Q4 2017 earnings at ($0.45) EPS, FY2018 earnings at ($1.75) EPS, FY2019 earnings at ($1.71) EPS and FY2020 earnings at ($0.88) EPS.
Several other research analysts also recently issued reports on the company. ValuEngine downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $28.00 price target on shares of TG Therapeutics in a research note on Tuesday, October 3rd. HC Wainwright reaffirmed a “buy” rating and set a $33.00 price target (up previously from $18.00) on shares of TG Therapeutics in a research note on Tuesday. Zacks Investment Research downgraded TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Finally, BidaskClub raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $26.78.
WARNING: This report was reported by Week Herald and is the sole property of of Week Herald. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://weekherald.com/2017/11/15/fy2017-eps-estimates-for-tg-therapeutics-inc-increased-by-jefferies-group-tgtx.html.
TG Therapeutics (NASDAQ:TGTX) opened at $8.65 on Monday. TG Therapeutics has a one year low of $4.10 and a one year high of $15.35.
TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.05). The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative return on equity of 151.21% and a negative net margin of 73,217.77%.
Institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. increased its position in TG Therapeutics by 44.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 364,025 shares of the biopharmaceutical company’s stock worth $3,658,000 after purchasing an additional 111,155 shares in the last quarter. Goldman Sachs Group Inc. increased its position in TG Therapeutics by 152.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 43,020 shares of the biopharmaceutical company’s stock worth $501,000 after purchasing an additional 26,001 shares in the last quarter. Dupont Capital Management Corp purchased a new stake in TG Therapeutics during the 2nd quarter worth about $258,000. Ameriprise Financial Inc. purchased a new stake in TG Therapeutics in the 1st quarter valued at about $1,291,000. Finally, Parametric Portfolio Associates LLC purchased a new stake in TG Therapeutics in the 1st quarter valued at about $928,000. Hedge funds and other institutional investors own 49.58% of the company’s stock.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.